Corwin covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Zevra Therapeutics, and Poseida Therapeutics. According to TipRanks, Corwin has an average return of 4.1% and a 50.79% ...
Currently, the analyst consensus on PTC Therapeutics is a Hold with an average price target of $42.40, a -5.1% downside from current levels. In a report issued on November 7, RBC Capital also ...
Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...
PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...
At the start of the year, the company said it expected to make as much as $1 billion in revenue ... 2024 Future of ...
Copyright © 2024 MarketWatch, Inc. All rights reserved.
Moving forward, Bettendorf's youth sports programs and coach-led camps can apply to use trademarked district logos, followed ...
The letter from the central bank to Krishi Bank stated that approval from the appropriate government authority – the Power ...
The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback